|
| Immunotherapy and fatigue: what we know and what we don’t know |
|
https://doi.org/10.18632/oncotarget.27946
Muhammad Azeem Khan, Vaia Florou, Umang Swami
|
| 719-720 |
|
| Drug exposure: still relevant after all these years |
|
https://doi.org/10.18632/oncotarget.27899
David E. Gerber, William C. Putnam
|
| 721-722 |
|
| Up to your NEK2 in CIN |
|
https://doi.org/10.18632/oncotarget.27918
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri
|
| 723-725 |
|
| Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra® |
|
https://doi.org/10.18632/oncotarget.27945
Tracey White, Szabolcs Szelinger, Janine LoBello, Amy King, Jessica Aldrich, Nathan Garinger, Matthew Halbert, Ryan F. Richholt, Stephen D. Mastrian, Cody Babb, Audrey A. Ozols, Laurie J. Goodman, Gargi D. Basu, Thomas Royce
|
| 726-739 |
|
| Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas |
|
https://doi.org/10.18632/oncotarget.27928
Chandni Desai, Jon Thomason, Jordan L. Kohlmeyer, Anna C. Reisetter, Parmanand Ahirwar, Khadijeh Jahanseir, Mariah Leidinger, Georgina Ofori-Amanfo, Karen Fritchie, Sadanandan E. Velu, Patrick Breheny, Dawn E. Quelle, Munir R. Tanas
|
| 740-755 |
|
| Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib |
|
https://doi.org/10.18632/oncotarget.27924
Yehia I. Mohamed, Sunyoung Lee, Lianchun Xiao, Manal M. Hassan, Aliya Qayyum, Rikita Hiatia, Roberto Carmagnani Pestana, Abedul Haque, Bhawana George, Asif Rashid, Dan G. Duda, Hesham Elghazaly, Robert A. Wolff, Jeffrey S. Morris, James Yao, Hesham M. Amin, Ahmed O. Kaseb
|
| 756-766 |
|
| Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability |
|
https://doi.org/10.18632/oncotarget.27935
Matthew A.M. Devall, Graham Casey
|
| 767-782 |
|
| Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens |
|
https://doi.org/10.18632/oncotarget.27941
Kamala Vanarsa, Shereen Enan, Pooja Patel, Briony Strachan, Anto Sam Crosslee Louis Sam Titus, Aphrihl Dennis, Yair Lotan, Chandra Mohan
|
| 783-790 |
|
| The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations |
|
https://doi.org/10.18632/oncotarget.27943
Aditya Kulkarni, Joseph Ryan McDermott, Umesh Kathad, Rama Modali, Jean-Philippe Richard, Panna Sharma, Kishor Bhatia
|
| 791-806 |
|
| Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer |
|
https://doi.org/10.18632/oncotarget.27932
Radhika R. Gudi, Harinarayanan Janakiraman, Philip H. Howe, Viswanathan Palanisamy, Chenthamarakshan Vasu
|
| 807-822 |
|
| Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth |
|
https://doi.org/10.18632/oncotarget.27940
Nathalie Sphyris, Cody King, Jonathan Hoar, Steven J. Werden, Geraldine V. Vijay, Naoyuki Miura, Akhilesh Gaharwar, Tapasree Roy Sarkar
|
| 823-844 |
|
| Predicting clinical outcomes using cancer progression associated signatures |
|
https://doi.org/10.18632/oncotarget.27934
Jared Mamrot, Nathan E. Hall, Robyn A. Lindley
|
| 845-858 |
|
| High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC |
|
https://doi.org/10.18632/oncotarget.27930
Elodie Montaudon, Rania El Botty, Sophie Vacher, Olivier Déas, Adnan Naguez, Sophie Chateau-Joubert, Damien Treguer, Ludmilla de Plater, Leïla Zemoura, Fariba Némati, André Nicolas, Alain Chapelier, Alain Livartowski, Stefano Cairo, Catherine Daniel, Marie Brevet, Elisabetta Marangoni, Didier Meseure, Sergio Roman-Roman, Ivan Bieche, Nicolas Girard, Didier Decaudin
|
| 859-872 |
